Mosquito-Borne Diseases in the World: A Complete Handbook

Malaria is caused by Plasmodium parasites — five species infect humans, but P. falciparum is responsible for the overwhelming majority of severe cases and deaths, particularly in sub-Saharan Africa. P. vivax is the most geographically widespread, extending into temperate zones where other species rarely reach. Transmission happens when a female Anopheles mosquito takes a blood meal at night — these mosquitoes are primarily dusk-to-dawn biters, which is a key behavioral trait that shapes all prevention strategies. The parasite travels from the mosquito’s saliva into the human bloodstream, migrates to the liver, and then re-enters the blood as merozoites that invade red blood cells. That liver stage is what makes early treatment complicated — infected people can feel completely fine for weeks.

Sub-Saharan Africa carries more than 94% of global malaria deaths, with children under five accounting for roughly 80% of those fatalities. Control has improved substantially through insecticide-treated bed nets, indoor residual spraying, and artemisinin-based combination therapies — but gains stalled after 2019 and COVID-era disruptions partially reversed progress. Drug resistance, particularly artemisinin partial resistance emerging in East Africa, is the sharpest current threat to control effectiveness. The RTS,S/AS01 vaccine (Mosquirix) offers partial protection (~30–40%) and is now being rolled out in high-burden countries, though it is not a substitute for sustained vector control.

Dengue fever is caused by any of four antigenically distinct serotypes (DENV-1 through DENV-4) of the Dengue virus, a flavivirus. The primary vector, Aedes aegypti, is a container-breeding urban mosquito that feeds aggressively during the day — particularly around dawn and late afternoon — which renders bed nets largely ineffective as a protection strategy. The virus replicates inside the mosquito over an extrinsic incubation period of roughly 8–12 days. When a person infected with one dengue serotype later encounters a different serotype, the immune response can amplify viral replication through antibody-dependent enhancement — this is the mechanism behind life-threatening dengue hemorrhagic fever in secondary infections.

Dengue is now endemic in over 130 countries and represents the fastest-spreading mosquito-borne viral disease globally, with cases roughly doubling each decade since the 1990s. Control is difficult because Aedes aegypti breeds in tiny amounts of water in urban environments — discarded bottles, clogged gutters, even flowerpot trays. Source reduction campaigns are the most cost-effective urban intervention. The Dengvaxia vaccine requires prior dengue exposure screening: administering it to dengue-naive individuals paradoxically increases severe disease risk, which remains a significant programmatic challenge for national immunization programs.

Zika virus is a flavivirus first identified in Uganda in 1947, but which remained obscure until explosive epidemics hit the Pacific Islands (2013–14) and then Brazil from 2015 onward. Like dengue, the primary vector is Aedes aegypti, and the transmission cycle is urban, daytime-biting, and container-breeding in nature. Most adults experience mild or no symptoms — simultaneously reassuring and epidemiologically dangerous, since silent transmission is nearly impossible to detect through passive surveillance. The virus’s capacity to cross the placenta and disrupt fetal brain development — causing microcephaly and other severe congenital abnormalities collectively termed Congenital Zika Syndrome — elevated it to a WHO Public Health Emergency of International Concern in 2016.

Zika is unusual among mosquito-borne diseases in that it can also be sexually transmitted, with the virus detected in semen weeks after acute infection resolves. This complicates control because mosquito-focused interventions alone are insufficient. Aedes albopictus — a hardier, cold-tolerant species — extends potential transmission zones considerably further north than aegypti alone. Since the 2015–16 epidemic peak, Zika activity has quieted considerably, but sporadic outbreaks continue and no approved vaccine exists. Several vaccine candidates are in clinical trials as of 2024–25. Prevention for pregnant women or those trying to conceive remains the primary public health focus.

Chikungunya is caused by Chikungunya virus (CHIKV), an alphavirus. The name comes from the Makonde language of Tanzania and translates roughly to “that which bends up” — a reference to the stooped posture caused by debilitating joint pain. The same two Aedes vectors responsible for dengue and Zika transmit it via an identical day-biting, urban cycle. A 2004–06 mutation in the E1 envelope glycoprotein allowed the virus to replicate efficiently in Aedes albopictus — a species far more tolerant of cooler climates — effectively doubling the vector’s geographic range and triggering the Indian Ocean epidemic of 2005–06 that infected over a million people.

Chikungunya rarely kills directly, but its burden of chronic disease is substantial. Estimates suggest 30–60% of patients develop persistent polyarthritis lasting months or even years after the acute phase, causing long-term disability and significant economic harm. An approved chikungunya vaccine (IXCHIQ) was authorized in the United States in late 2023, making it one of the newest additions to the arboviral vaccine toolkit. Community-level control mirrors dengue strategies: eliminating Aedes breeding sites, larviciding, and targeted adulticiding during outbreaks. Given the shared vector, co-infection with dengue and Zika in the same individual is documented and creates diagnostic complexity.

West Nile Virus is a flavivirus maintained in nature through an enzootic cycle between birds — the amplifying reservoir hosts — and Culex mosquitoes. Humans, horses, and other mammals are incidental dead-end hosts: the virus replicates in them but typically doesn’t reach high enough viremia to infect a feeding mosquito, breaking the transmission chain. Culex mosquitoes are primarily crepuscular and nocturnal biters, active dusk through night. The virus arrived in North America in 1999 — first detected in New York City — and spread rapidly across the continent, exploiting the enormous diversity of North American bird species as reservoir hosts.

Approximately 80% of WNV infections are asymptomatic. Around 20% cause West Nile Fever — a self-limiting febrile illness. Less than 1% progress to neuroinvasive disease (encephalitis, meningitis, or flaccid paralysis), but that fraction carries a ~10% case fatality rate and significant long-term neurological morbidity in survivors. Elderly and immunocompromised individuals are disproportionately at risk. Annual WNV activity in the US is closely tied to summer weather: hot, dry conditions that concentrate bird and mosquito populations around remaining water sources tend to produce larger outbreaks. Vector control relies on Culex larval surveillance, larviciding, and aerial adulticiding during outbreak conditions.

Yellow Fever virus (YFV) is a flavivirus that exists in three transmission cycles: a sylvatic (jungle) cycle involving non-human primates and forest-dwelling mosquitoes (Haemagogus in South America; Aedes africanus in Africa); an intermediate savanna cycle in Africa involving semi-domestic Aedes species; and an urban cycle driven by Aedes aegypti that can amplify explosively in cities with low vaccination coverage. The disease causes a spectrum of illness — most infections are mild — but the “toxic phase” characterized by jaundice, hemorrhage, and multi-organ failure occurs in roughly 15% of cases and carries a case fatality rate of up to 50% even with supportive care.

Sub-Saharan Africa accounts for approximately 90% of global yellow fever deaths. The disease is vaccine-preventable: the 17D vaccine strain, developed in the 1930s, is one of the safest and most effective vaccines ever produced, conferring lifelong immunity in most recipients from a single dose. Despite this, vaccination coverage gaps persist — particularly in high-risk African countries — and urban outbreaks re-emerged in Angola, the Democratic Republic of Congo, and Brazil in recent years, driven by vaccine-naive urban populations and ongoing encroachment on forested areas. WHO maintains emergency vaccine stockpiles for rapid outbreak response.

Japanese Encephalitis virus (JEV) is a flavivirus that circulates in a zoonotic cycle primarily involving Culex tritaeniorhynchus mosquitoes, wading birds (herons, egrets) as reservoir hosts, and pigs as amplifying hosts. Humans are incidental dead-end hosts. The mosquito breeds in flooded rice paddies and irrigated agricultural land — which is why JE is overwhelmingly a disease of rural Asia, concentrated in farming communities near water and pigs. JEV has spread progressively in recent decades, with documented expansion into northern Australia (2022), raising concerns about continued geographic spread driven by migratory birds.

Most JEV infections (estimated >99%) are asymptomatic or produce undifferentiated febrile illness. But among the ~68,000 clinical encephalitis cases per year, consequences are devastating: case fatality rates of 20–30%, with 30–50% of survivors experiencing permanent neurological or psychiatric sequelae. Children under 15 bear the highest burden. JE vaccines are highly effective and have substantially reduced incidence in countries with strong immunization programs — Japan, South Korea, and China have nearly eliminated JE through vaccination. In communities without high coverage, pig vaccination and Culex larval control in rice paddies remain the primary structural interventions.

Rift Valley Fever is caused by Rift Valley Fever phlebovirus (Phenuiviridae family) — distinct from the flaviviruses and alphaviruses dominating most of this list. It is primarily a disease of livestock — cattle, sheep, goats — with humans acquiring infection either through mosquito bites or, more commonly, through direct contact with infected animal blood, fluids, or tissues during slaughter and veterinary work. The primary maintenance vectors are flood-water Aedes species, particularly Aedes mcintoshi, whose drought-resistant eggs hatch in massive numbers after heavy rainfall floods low-lying areas — a flood event effectively triggers a livestock epizootic that can then spill over to humans.

Endemic in sub-Saharan Africa and the Arabian Peninsula, RVF outbreaks are closely tied to rainfall anomalies, particularly El Niño-linked flooding events. Large outbreaks occurred in East Africa in 1997–98, Saudi Arabia and Yemen in 2000, and East Africa again in 2006–07 and 2023–24. Human disease ranges from mild febrile illness to hemorrhagic fever, encephalitis, and retinitis that can cause permanent blindness — the ocular complication being particularly unusual among mosquito-borne diseases. Control effectiveness is highest when satellite-based early warning systems (predicting flooding and vegetation anomalies linked to Aedes breeding) are coupled with rapid livestock vaccination campaigns before human spillover scales.

Eastern Equine Encephalitis virus (EEEV) is an alphavirus maintained in a transmission cycle between Culiseta melanura mosquitoes and passerine birds in freshwater hardwood swamps along the eastern United States and Gulf Coast. Culiseta melanura rarely bites humans — it feeds almost exclusively on birds. What makes EEE a human health threat is the role of “bridge vectors”: generalist species like Aedes canadensis and Coquillettidia perturbans that feed on both birds and mammals, carrying the virus out of swamp ecosystems and into contact with horses and people. This indirect pathway is why EEE remains geographically constrained to specific swamp ecosystems even as capable bridge vectors are widespread.

EEE is rare — typically fewer than 10–15 confirmed human cases per year in the United States — but it has the highest case fatality rate of any mosquito-borne encephalitis in North America, at approximately 30%. Survivors frequently suffer severe and permanent neurological damage. There is no approved human vaccine and no specific antiviral treatment. The 2019 outbreak was an unusually severe year in the northeastern US, prompting several states to close outdoor evening events — a reminder that rare does not mean ignorable. Control relies on environmental risk modeling, sentinel chicken seroconversion monitoring, and aerial adulticide spraying in high-risk townships, with ongoing debate about non-target species impacts.

Western Equine Encephalitis virus (WEEV) is an alphavirus with a transmission cycle driven primarily by Culex tarsalis, strongly associated with irrigated agricultural land in the western United States and Canada. The enzootic cycle runs between Culex tarsalis and passerine birds — house sparrows and house finches are considered primary amplifying hosts. Horses and humans are dead-end hosts. The disease was a significant public health problem in the mid-20th century, with major outbreaks across the Great Plains and prairie regions of North America, but WEE incidence has declined dramatically since the 1980s for reasons that remain only partially understood.

The last confirmed human case of WEE in the United States occurred in 1994; the last recognized Canadian outbreak was in 1975. Despite this prolonged absence, WEEV continues to circulate in Culex tarsalis and bird populations across the western US, and Argentina and Brazil still report sporadic equine cases. Case fatality in humans is estimated at 3–7%, lower than EEE, but with notable neurological morbidity in survivors, particularly in infants. Any re-emergence would likely catch health systems unprepared given the decades of dormancy — a concern as climate shifts alter Culex tarsalis habitat range.

St. Louis Encephalitis virus (SLEV) is a flavivirus closely related to West Nile Virus and Japanese Encephalitis Virus — all three belong to the Japanese encephalitis antigenic complex. The transmission cycle mirrors WNV: birds serve as amplifying reservoir hosts, Culex mosquitoes transmit the virus, and humans are incidental dead-end hosts. Culex pipiens is the primary urban-suburban vector in the eastern United States; Cx. tarsalis dominates in the rural west and southwest. The disease gained its name from a major 1933 epidemic in St. Louis that infected hundreds and killed dozens.

SLE activity has diminished significantly since West Nile Virus arrived in North America in 1999, possibly due to cross-reactive immunity between the two closely related flaviviruses — though this relationship isn’t fully characterized. SLE still circulates and causes sporadic human cases, particularly in the southern United States and in South America, where SLEV activity has been documented in Argentina, Brazil, and Uruguay. Most SLE infections are asymptomatic; symptomatic disease ranges from mild febrile illness to encephalitis with case fatality rates of 5–15%, with elderly adults most at risk. Control mirrors WNV management: Culex surveillance, larviciding, and outbreak-triggered adulticiding.

La Crosse Encephalitis virus (LACV) is an orthobunyavirus transmitted primarily by Aedes triseriatus, the eastern treehole mosquito, which breeds almost exclusively in water-filled tree holes and discarded containers in forested areas. LACV is also transovarially transmitted — infected female mosquitoes pass the virus directly to their eggs, ensuring the virus persists through winter without requiring an active vertebrate host. Chipmunks and squirrels serve as amplifying vertebrate hosts. This specific ecological niche largely defines La Crosse’s geographic distribution: forested areas of the midwestern, Appalachian, and eastern United States.

La Crosse is one of the leading causes of pediatric viral encephalitis in the United States, causing roughly 80–100 confirmed cases per year, primarily in children under 16. Adults are rarely affected, likely due to widespread subclinical exposure and acquired immunity. A significant proportion of child survivors experience long-term neurological effects including seizure disorders, behavioral changes, and cognitive impairment. Aedes albopictus — now established across much of the eastern US — has been identified as a competent experimental vector for LACV, raising concerns it could expand the disease’s range. Control is difficult: natural treeholes cannot be eliminated, making source reduction less effective than for urban container-breeding Aedes.

O’nyong-nyong virus (ONNV) is an alphavirus closely related to Chikungunya — sharing about 80% nucleotide sequence similarity — and clinically produces an almost identical syndrome: sudden fever, severe joint pain, rash, and lymphadenopathy. What makes it epidemiologically unusual is its vector: unlike nearly all other alphaviruses, which are transmitted by Aedes species, ONNV is transmitted by Anopheles mosquitoes — the same genus responsible for malaria transmission. The name comes from the Acholi language of Uganda and means “joint breaker.” ONNV caused one of the largest arboviral epidemics in recorded history when it emerged in Uganda in 1959, infecting an estimated 2 million people in under two years.

A second large outbreak occurred in Uganda in 1996–97; since then, sporadic transmission has been documented in West and Central Africa, but no further major epidemic has occurred — a pattern that remains unexplained. The relationship between ONNV and malaria vector control programs is poorly studied: theoretically, interventions targeting Anopheles for malaria could reduce ONNV transmission as a co-benefit, though this has not been formally evaluated. Low mortality and the absence of vaccines or specific treatments mean ONNV rarely commands research funding commensurate with its historical epidemic potential.

Mayaro virus is an alphavirus first isolated in Trinidad in 1954, endemic in forested areas of South America — particularly the Amazon Basin regions of Brazil, Bolivia, Peru, and Venezuela. The primary transmission cycle is sylvatic, driven by Haemagogus janthinomys, a forest-canopy mosquito that feeds on non-human primates and occasionally on humans entering forested areas. Marmosets and other neotropical primates serve as amplifying reservoir hosts. Mayaro’s clinical presentation is nearly indistinguishable from chikungunya — high fever, severe arthralgia, rash — and the two are frequently confused in clinical settings, which likely contributes to Mayaro being systematically underreported.

The key concern is the possibility of urban emergence. Aedes aegypti has been experimentally infected with MAYV and can transmit it in laboratory conditions, raising the prospect of an urban transmission cycle developing in cities with high aegypti density — similar to what occurred with chikungunya. Cases in Brazilian cities have been documented. No vaccine or specific treatment exists. Current surveillance is sparse, with most Mayaro data coming from forest worker cohort studies rather than systematic national surveillance. The risk level for most travelers is low, but researchers have flagged its silent epidemic potential as not being matched by current investment in monitoring or countermeasure development.

Ross River Virus is an alphavirus endemic to Australia and parts of the Pacific Islands, and is the most common mosquito-borne disease in Australia by case count — roughly 5,000+ notified cases per year. Multiple mosquito species are involved: Culex annulirostris is the primary inland freshwater vector; Aedes vigilax dominates in coastal salt-marsh environments. Macropods — kangaroos and wallabies — along with other marsupials serve as reservoir hosts, creating a transmission cycle deeply embedded in Australian wildlife ecology that is difficult to disrupt through conventional vector control targeting domestic environments.

Ross River Virus disease (epidemic polyarthritis) produces joint pain, fatigue, and rash predominantly affecting small joints — fingers, wrists, ankles, and knees. What sets RRV apart is duration: many patients report joint pain, fatigue, and depression persisting for months, with a subset experiencing symptoms beyond a year. No fatalities are attributed to RRV infection, but the economic burden from lost workdays and healthcare utilization is substantial. No licensed vaccine exists — trial vaccines have been developed but none has reached licensure. Prevention relies on personal protection, with source reduction largely impractical given the involvement of natural wetland habitats and wildlife reservoirs.

Barmah Forest Virus is an alphavirus found exclusively in Australia — the only country where it has been documented in humans. First isolated in 1974 from mosquitoes in the Barmah Forest on the Murray River in Victoria, the virus causes a clinical syndrome nearly identical to Ross River Virus: polyarthritis, rash, fever, and fatigue. It is transmitted by many of the same mosquito species, including Culex annulirostris and Aedes vigilax, and shares similar ecological associations with wetland habitats. The reservoir host is not definitively established — marsupials are suspected, but the evidence is less solid than for RRV.

Barmah Forest Virus disease generates typically 1,000–2,000 cases per year in Australia, concentrated in coastal Queensland and New South Wales following wet seasons — considerably fewer than RRV. The clinical course is broadly similar to RRV but generally considered milder and shorter in duration. Co-infection with RRV is possible and has been documented, though uncommon. No vaccine exists. BFV serves as a useful case study in how a geographically restricted alphavirus is contained at least partly by its island-continent isolation — raising the theoretical question of what would happen if it were introduced to regions with susceptible local vector populations.

Venezuelan Equine Encephalitis encompasses a complex of alphaviruses divided into epizootic and enzootic subtypes. The enzootic strains circulate quietly in rodent-mosquito cycles in lowland tropical forest habitats of Central and South America, transmitted by mosquitoes that rarely contact humans — causing sporadic cases but not large outbreaks. The epizootic strains (subtypes IAB and IC) are the dangerous ones: they amplify explosively in equine populations — horses, donkeys, mules — producing extremely high viremias in these animals, which are then picked up by a wide range of opportunistic mosquito species including Aedes, Psorophora, and Mansonia that readily feed on humans. The horse becomes a virus amplification machine that bridges the sylvatic cycle to human populations.

Major VEE epidemics affected Central America and the United States in 1969–71, killing tens of thousands of horses and causing an estimated 500,000 human cases with around 300 deaths. More recent epizootic outbreaks occurred in Venezuela and Colombia in the 1990s. Most human VEE infections cause acute febrile illness; only around 4% of adults (higher in children) progress to encephalitis. A military vaccine (TC-83) exists but is not licensed for civilian use, restricted to laboratory workers and military personnel at high risk. In the absence of a licensed vaccine, equine vaccination during epizootic alert periods is the most critical control tool — stopping amplification in horses cuts human transmission significantly.

Lymphatic Filariasis (LF) is caused by parasitic filarial worms — primarily Wuchereria bancrofti (responsible for ~90% of cases), Brugia malayi, and Brugia timori — transmitted through mosquito bites. Unlike viral mosquito-borne diseases that cause acute illness, LF is a chronic, progressive disease. Infective larvae deposited during a mosquito bite migrate to the lymphatic system, develop into adult worms over 6–12 months, and can live for years — triggering inflammatory responses that progressively damage lymphatic vessels. The resulting lymphedema can advance to elephantiasis, a profoundly disabling condition involving grotesque swelling of the limbs and genitals. In urban settings across Africa, Culex quinquefasciatus is the primary vector — it thrives in polluted, stagnant water associated with poor sanitation infrastructure, giving LF a strong association with poverty.

Approximately 51 million people are currently infected globally, with around 863 million at risk across 72 countries. Sub-Saharan Africa, South Asia, and Southeast Asia carry the heaviest burden. WHO’s Global Programme to Eliminate Lymphatic Filariasis (GPELF), launched in 2000, uses mass drug administration (MDA) of ivermectin, albendazole, and diethylcarbamazine to interrupt transmission — one of the more successful neglected tropical disease elimination programs to date, having substantially reduced the number of infected people over two decades. Combining MDA with vector control accelerates progress; elimination has been certified in several Pacific Island nations and parts of Asia.

Sindbis virus is an alphavirus with one of the widest geographic distributions of any arbovirus — isolated from Africa, Europe, Asia, and Australia. It circulates in bird-mosquito transmission cycles involving multiple Culex and Culiseta species, with passerine birds as primary reservoir hosts. In northern Europe — Finland, Sweden, and Russia — seasonal Sindbis fever outbreaks, locally known as “Ockelbo disease” in Sweden and “Pogosta disease” in Finland, follow predictable summer patterns tied to the hatching of Culex and Culiseta populations in boreal forest habitats. These outbreaks cluster in forested areas where bird and mosquito densities are high, affecting rural residents and outdoor workers.

Sindbis disease produces a triad of rash, arthritis, and fatigue similar to Ross River and Barmah Forest virus diseases. Joint symptoms — affecting knees, ankles, wrists, and small joints — can persist for months in a substantial minority of patients, though deaths are essentially unknown. Most infections in Africa and Asia go undiagnosed, either asymptomatic or attributed to other febrile illnesses. No vaccine exists. Sindbis has a low public profile partly because it doesn’t cause the acute encephalitis or hemorrhagic fever that attracts emergency response funding, and partly because its burden falls mainly in high-latitude countries with well-functioning health systems. It serves as a useful case study in how an alphavirus can be simultaneously widespread, clinically significant, and almost entirely absent from global public health priority lists.